Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019
Multiple myeloma (MM) is a rare hematologic malignancy with a 5-year survival rate of 52 %. For transplant-eligible MM patients, high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is recommended. Given the complexities of the ASCT procedure, understanding patient-specific fact...
Saved in:
| Main Authors: | Whanhui Chi, Juhyeon Song, Tyler J. Varisco |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000864 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Autologous stem cell transplantation in multiple myeloma at Chris Hani Baragwanath Academic Hospital
by: Vedanand Rawoo, et al.
Published: (2025-04-01) -
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01) -
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020
by: Laure Vincent, et al.
Published: (2025-03-01) -
ASCT2 inhibits HIV-1 infectivity by promoting the incorporation of a gp160/ASCT2 complex into virions
by: Luciana Morellatto Ruggieri, et al.
Published: (2025-08-01) -
THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Anuj Mahindra, et al.
Published: (2010-05-01)